Form 4 for PHAT Phathom Pharmaceuticals, Inc.
Accepted 2023-07-17 00:00:00 ET · period of report 2023-07-14 · accession 0001209191-23-042454 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-07-17 | 2023-07-14 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | A - Grant | — | +200.0K | 389.7K | +105% | — |
| DM | 2023-07-17 | 2023-07-14 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | D - Sale to Iss | — | -400.0K | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-14 | A | A | 200,000 | — | 389,671 | D | — | — | (F1) On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. (F2) Includes 1,381 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023. |
| 2 | Derivative | Stock Option | 2023-07-14 | D | D | 225,000 | — | 0 | D | $39.11 · — to 2031-01-27 | 225,000 Common Stock | (F1) On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. |
| 3 | Derivative | Stock Option | 2023-07-14 | D | D | 175,000 | — | 0 | D | $32.20 · — to 2030-06-30 | 175,000 Common Stock | (F1) On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. |